ArteraAI Stock

artera.aiHealthcare / BioTech & PharmaFounded: 2021Funding to Date: $89.5MM

Artera, founded in 2021, is a precision medicine company and the developer of multimodal artificial intelligence-based predictive and prognostic tests with the goal of personalizing therapy for cancer patients. Artera’s flagship test is the ArteraAI Prostate Test, seeking to predict therapy benefit in localized prostate cancer. Artera is headquartered in Los Altos, California.

Register To Buy and Sell Shares

For more details on financing and valuation for ArteraAI, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access ArteraAI’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like ArteraAI.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Andre Esteva Ph.D
Co-Founder, Chief Executive Officer & Board Member

Frequently Asked Questions About ArteraAI’s Stock

Can you buy ArteraAI’s stock?
ArteraAI is not publicly traded on NYSE or NASDAQ in the U.S. To buy ArteraAI’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell ArteraAI’s stock?
Yes, you can sell stock of a private company like ArteraAI. Forge can help you sell your ArteraAI stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is ArteraAI’s stock price?
ArteraAI is a privately held company and therefore does not have a public stock price. However, you may access ArteraAI’s private market stock price with Forge Data.
What is ArteraAI’s stock ticker symbol?
ArteraAI does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Tech company Artera launches solution to help health systems manage all those texts, emails to patients
Health systems have made big investments in the past few years to build out "digital front doors" for patients. But in many cases, all these "doors" lead down different hallways, resulting in a fragmented, disjointed experience for patients. All these communication tools also cause headaches for healthcare staff to manage.
Artera snags $90M for prostate cancer test
Artera, a medical company developing AI tests to personalize therapy for cancer patients, raised $90 million, the company tells Axios exclusively.
Cancer-Testing Startup Artera Raises $90M
Artera, which uses artificial intelligence for cancer testing and personalized care, raised a $90 million round to support the distribution of its flagship test in prostate cancer.
Updated on: May 22, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.